CD274 and neoplasm: The phase III KEYNOTE-189 (NCT02578680) study confirmed the clinical benefit of first-line pembrolizumab plus pemetrexed and platinum in patients with non-squamous metastatic NSCLC, regardless of PD-L1 tumor expression [87].